Biocompatibles International plc is a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010, which was, in turn, acquired by Boston Scientific in 2019. Approved oncology products are supplied and marketed from facilities in Farnham, Surrey, UK and Oxford, Connecticut. Its UK research and development facilities are engaged in licensing and in new product development based on the company's core drug delivery technologies in the treatment of cancers.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| |
rdfs:comment
| - Biocompatibles International plc is a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010, which was, in turn, acquired by Boston Scientific in 2019. Approved oncology products are supplied and marketed from facilities in Farnham, Surrey, UK and Oxford, Connecticut. Its UK research and development facilities are engaged in licensing and in new product development based on the company's core drug delivery technologies in the treatment of cancers. (en)
|
foaf:name
| |
foaf:homepage
| |
name
| |
foaf:depiction
| |
location
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
foundation
| |
homepage
| |
industry
| |
key people
| |
location
| |
logo
| - Biocompatibles logo.png (en)
|
logo size
| |
num employees
| |
products
| |
traded as
| |
type
| |
has abstract
| - Biocompatibles International plc is a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010, which was, in turn, acquired by Boston Scientific in 2019. Approved oncology products are supplied and marketed from facilities in Farnham, Surrey, UK and Oxford, Connecticut. Products include drug-eluting bead products that are used in more than 35 countries for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and other cancers. The company supplies and markets brachytherapy products (radiation-delivering seeds) that are used to treat prostate cancer. Its UK research and development facilities are engaged in licensing and in new product development based on the company's core drug delivery technologies in the treatment of cancers. Its Cellmed unit in Alzenau, Germany, is developing a drug-eluting bead product for the treatment of stroke based on proprietary stem cell technology. Cellmed is also developing a GLP-1 analogue for the treatment of diabetes and obesity partnered with AstraZeneca. Biocompatibles has collaborative agreements with Bayer HealthCare Pharmaceuticals Inc., Medtronic Inc. and Merz Pharma. (en)
|
skos:closeMatch
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
founding year
| |
number of employees
| |